Risk of malignancy in patients treated for systemic necrotising vasculitis

Ann Rheum Dis. 2020 Mar;79(3):431-433. doi: 10.1136/annrheumdis-2019-216452. Epub 2019 Nov 25.

Antoine Lafarge^{1

2}, Adrien Joseph³, Christian Pagnoux⁴, Xavier Puechal^{5

2}, Pacal Cohen^{5

2}, Maxime Samson⁶, Mohamed Hamidou⁷, Alexandre Karras⁸, Matthieu Groh⁵, Thomas Quemeneur⁹, Camillo Ribi¹⁰, Luc Mouthon^{5

2

11}, Loic Guillevin^{5

2

11}, Benjamin Terrier^{1

2

11}; French Vasculitis Study Group (FVSG)

¹ Department of Internal Medicine, Cochin Hospital, Paris, France antoinelafarge@outlook.com benjamin.terrier@aphp.fr.
² National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France.
³ U1138, INSERM, Paris, France.
⁴ Department of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada.
⁵ Department of Internal Medicine, Cochin Hospital, Paris, France.
⁶ Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, Dijon, France.
⁷ Department of Internal Medicine, Hôtel Dieu, Nantes, France.
⁸ Department of Nephrology, Hôpital Européen Georges Pompidou, Paris, France.
⁹ Department of Internal Medicine, Hôpital de Valenciennes, Valenciennes, France.
¹⁰ Department of Immunology, CHUV, Lausanne, Switzerland.
¹¹ Paris Descartes University, Paris, France.

No abstract available

Keywords: cancer; cyclophoshamide; immunosuppressive agents; rituximab; vasculitis.

Publication types